Mirum Pharmaceuticals Inc (NASDAQ: MIRM) closed the day trading at $26.99 down -0.07% from the previous closing price of $27.01. In other words, the price has decreased by -$0.02 from its previous closing price. On the day, 653239 shares were traded.
Ratios:
For a better understanding of MIRM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.19 and its Current Ratio is at 4.45. In the meantime, Its Debt-to-Equity ratio is 1.24 whereas as Long-Term Debt/Eq ratio is at 1.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 18, 2023, Reiterated its Buy rating but revised its target price to $58 from $60 previously.
On November 13, 2023, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $60.Morgan Stanley initiated its Overweight rating on November 13, 2023, with a $60 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 18 ’24 when BJERKHOLT ERIC bought 2,000 shares for $25.80 per share. The transaction valued at 51,600 led to the insider holds 12,000 shares of the business.
Peetz Christopher sold 6,013 shares of MIRM for $157,491 on Feb 02 ’24. The CHIEF EXECUTIVE OFFICER now owns 104,112 shares after completing the transaction at $26.19 per share. On Feb 02 ’24, another insider, Radovich Peter, who serves as the PRESIDENT AND COO of the company, sold 1,790 shares for $26.19 each. As a result, the insider received 46,883 and left with 34,695 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MIRM now has a Market Capitalization of 1.27B and an Enterprise Value of 1.29B. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.75 while its Price-to-Book (P/B) ratio in mrq is 5.07. Its current Enterprise Value per Revenue stands at 6.92 whereas that against EBITDA is -9.45.
Stock Price History:
Over the past 52 weeks, MIRM has reached a high of $35.56, while it has fallen to a 52-week low of $21.83. The 50-Day Moving Average of the stock is 27.54, while the 200-Day Moving Average is calculated to be 28.40.
Shares Statistics:
Over the past 3-months, MIRM traded about 611.57K shares per day on average, while over the past 10 days, MIRM traded about 750.26k shares per day. A total of 46.72M shares are outstanding, with a floating share count of 36.61M. Insiders hold about 21.47% of the company’s shares, while institutions hold 91.34% stake in the company. Shares short for MIRM as of Feb 29, 2024 were 7.66M with a Short Ratio of 12.53, compared to 7.85M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 16.44% and a Short% of Float of 18.06%.
Earnings Estimates
Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of -$0.44 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.57, while EPS last year was -$0.8. The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.07 and low estimates of -$0.71.
Analysts are recommending an EPS of between -$0.25 and -$2.48 for the fiscal current year, implying an average EPS of -$1.23. EPS for the following year is $0.75, with 9 analysts recommending between $2.47 and -$0.9.
Revenue Estimates
7 analysts predict $71.1M in revenue for the current quarter. It ranges from a high estimate of $72.9M to a low estimate of $69.6M. As of the current estimate, Mirum Pharmaceuticals Inc’s year-ago sales were $28.69M, an estimated increase of 147.80% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $75.92M, an increase of 149.40% over than the figure of $147.80% in the same quarter last year. There is a high estimate of $79.5M for the next quarter, whereas the lowest estimate is $73M.
A total of 8 analysts have provided revenue estimates for MIRM’s current fiscal year. The highest revenue estimate was $325.5M, while the lowest revenue estimate was $310M, resulting in an average revenue estimate of $316.93M. In the same quarter a year ago, actual revenue was $186.37M, up 70.10% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $433.36M in the next fiscal year. The high estimate is $509.43M and the low estimate is $378M. The average revenue growth estimate for next year is up 36.70% from the average revenue estimate for this year.
